HERON THERAPEUTICS, INC. /DE/ (HRTX) Free cash flow 2016–2025
HERON THERAPEUTICS, INC. /DE/ (HRTX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$27.9MFY2025 · since FY2016: -$137.2M → -$27.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$27.9M | -15.2% |
| FY2024 | -$24.2M | +59.8% |
| FY2023 | -$60.3M | +59.4% |
| FY2022 | -$148.7M | +27.9% |
| FY2021 | -$206.4M | -7.7% |
| FY2020 | -$191.6M | -45.5% |
| FY2019 | -$131.7M | +34.5% |
| FY2018 | -$201.0M | -16.3% |
| FY2017 | -$172.9M | -26.0% |
| FY2016 | -$137.2M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More HRTX financial trends
HRTX RevenueHRTX Net incomeHRTX Net marginHRTX Gross profitHRTX Gross marginHRTX Operating incomeHRTX Operating marginHRTX Operating cash flowHRTX Capital expendituresHRTX Return on equityHRTX Stock buybacksHRTX Dividends paidHRTX Total assetsHRTX Total liabilitiesHRTX Shareholders’ equityHRTX overview →